Search Results - "Schrauder, A"

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 by Möricke, A, Zimmermann, M, Reiter, A, Henze, G, Schrauder, A, Gadner, H, Ludwig, W D, Ritter, J, Harbott, J, Mann, G, Klingebiel, T, Zintl, F, Niemeyer, C, Kremens, B, Niggli, F, Niethammer, D, Welte, K, Stanulla, M, Odenwald, E, Riehm, H, Schrappe, M

“…Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin–Frankfurt–Münster (BFM) study group for childhood…”
Get full text

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 by Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O G, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A K, Foà, R, Gökbuget, N, Goldstone, A H, Goulden, N, Henze, G, Hoelzer, D, Janka-Schaub, G E, Macintyre, E A, Pieters, R, Rambaldi, A, Ribera, J-M, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, van Dongen, J J M

“…Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia…”
Get full text

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol by Dörge, Petra, Meissner, Barbara, Zimmermann, Martin, Möricke, Anja, Schrauder, André, Bouquin, Jean-Pierre, Schewe, Denis, Harbott, Jochen, Teigler-Schlegel, Andrea, Ratei, Richard, Ludwig, Wolf-Dieter, Koehler, Rolf, Bartram, Claus R, Schrappe, Martin, Stanulla, Martin, Cario, Gunnar

“…IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor B-cell acute lymphoblastic leukemia. To assess the prognostic relevance of…”
Get full text

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia by Flohr, T, Schrauder, A, Cazzaniga, G, Panzer-Grümayer, R, van der Velden, V, Fischer, S, Stanulla, M, Basso, G, Niggli, F K, Schäfer, B W, Sutton, R, Koehler, R, Zimmermann, M, Valsecchi, M G, Gadner, H, Masera, G, Schrappe, M, van Dongen, J J M, Biondi, A, Bartram, C R

“…Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in…”
Get full text

Analysis of minimal residual disease by Ig TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data by VAN DER VELDEN, V. H. J, CAZZANIGA, G, CAYUELA, J. M, TRKA, J, ECKERT, C, FORONI, L, ZUR STADT, U, BELDJORD, K, RAFF, T, VAN DER SCHOOT, C. E, VAN DONGEN, J. J. M, SCHRAUDER, A, HANCOCK, J, BADER, P, PANZER-GRUMAYER, E. R, FLOHR, T, SUTTON, R, CAVE, H, MADSEN, H. O

“…Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD…”
Get full text

Bloodstream infection in paediatric cancer centres—leukaemia and relapsed malignancies are independent risk factors by Ammann, R. A., Laws, H. J., Schrey, D., Ehlert, K., Moser, O., Dilloo, D., Bode, U., Wawer, A., Schrauder, A., Cario, G., Laengler, A., Graf, N., Furtwängler, R., Simon, A.

“…In a prospective multicentre study of bloodstream infection (BSI) from November 01, 2007 to July 31, 2010, seven paediatric cancer centres (PCC) from Germany…”
Get full text

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia by GAIPA, Giuseppe, CAZZANIGA, Giovanni, SALA, Simona, SCHUMICH, Angela, SCHRAUDER, Andre, VILLA, Tiziana, VELTRONI, Marinella, LUDWIG, Wolf-Dieter, CONTER, Valentino, SCHRAPPE, Martin, BIONDI, Andrea, DWORZAK, Michael N, GRAZIA VALSECCHI, Maria, BASSO, Giuseppe, PANZER-GRÜMAYER, Renate, BULDINI, Barbara, SILVESTRI, Daniela, KARAWAJEW, Leonid, MAGLIA, Oscar, RATEI, Richard, BENETELLO, Alessandra

“…Flow cytometric analysis of leukemia-associated immunophenotypes and polymerase chain reaction-based amplification of antigen-receptor genes rearrangements are…”
Get full text

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting by VAN DER VELDEN, V. H. J, PANZER-GRÜMAYER, E. R, BARTRAM, C. R, MASERA, G, BIONDI, A, VAN DONGEN, J. J. M, CAZZANIGA, G, FLOHR, T, SUTTON, R, SCHRAUDER, A, BASSO, G, SCHRAPPE, M, WIJKHUIJS, J. M, KONRAD, M

“…Minimal residual disease (MRD) diagnostics is used for treatment stratification in childhood acute lymphoblastic leukemia. We aimed to identify and solve…”
Get full text

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients by Kellner, C, Zhukovsky, E A, Pötzke, A, Brüggemann, M, Schrauder, A, Schrappe, M, Kneba, M, Repp, R, Humpe, A, Gramatzki, M, Peipp, M

Get full text

Dental status does not predict infection during stem cell transplantation: a single-center survey by Guenther, A, Losch, E, Schiessl, M, Schrauder, A, Humpe, A, Repp, R, Nitsche, T, Wiltfang, J, Gramatzki, M

Get full text

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective by Schub, N, Günther, A, Schrauder, A, Claviez, A, Ehlert, C, Gramatzki, M, Repp, R

“…The efficacy and safety of CD52 antibody alemtuzumab to treat severe acute GVHD in 18 consecutive patients refractory to standard high-dose corticosteroid…”
Get full text

Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia by Preuner, Sandra, Peters, Christina, Pötschger, Ulrike, Daxberger, Helga, Fritsch, Gerhard, Geyeregger, Rene, Schrauder, André, von Stackelberg, Arend, Schrappe, Martin, Bader, Peter, Ebell, Wolfram, Eckert, Cornelia, Lang, Peter, Sykora, Karl-Walter, Schrum, Johanna, Kremens, Bernhard, Ehlert, Karoline, Albert, Michael H, Meisel, Roland, Lawitschka, Anita, Mann, Georg, Panzer-Grümayer, Renate, Güngör, Tayfun, Holter, Wolfgang, Strahm, Brigitte, Gruhn, Bernd, Schulz, Ansgar, Woessmann, Wilhelm, Lion, Thomas

“…Allogeneic hematopoietic stem cell transplantation is required as rescue therapy in about 20% of pediatric patients with acute lymphoblastic leukemia. However,…”
Get full text

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol by Van der Velden, V H J, Corral, L, Valsecchi, M G, Jansen, M W J C, De Lorenzo, P, Cazzaniga, G, Panzer-Grümayer, E R, Schrappe, M, Schrauder, A, Meyer, C, Marschalek, R, Nigro, L L, Metzler, M, Basso, G, Mann, G, Den Boer, M L, Biondi, A, Pieters, R, Van Dongen, J J M

“…Acute lymphoblastic leukemia (ALL) in infants younger than 1 year is a rare but relatively homogeneous disease (∼80% MLL gene rearranged, ∼70% CD10-negative)…”
Get full text

Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement by JANSEN, M. W. J. C, CORRAL, L, VALSECCHI, M. G, BASSO, G, BIONDI, A, PIETERS, R, VAN DONGEN, J. J. M, VAN DER VELDEN, V. H. J, PANZER-GRÜMAYER, R, SCHRAPPE, M, SCHRAUDER, A, MARSCHALEK, R, MEYER, C, DEN BOER, M. L, HOP, W. J. C

“…The aim of this study was to identify immunobiological subgroups in 133 infant acute lymphoblastic leukemia (ALL) cases as assessed by their immunophenotype,…”
Get full text

Very early early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment by Eckert, C, Flohr, T, Koehler, R, Hagedorn, N, Moericke, A, Stanulla, M, Kirschner-Schwabe, R, Cario, G, Stackelberg, Av, Bartram, C R, Henze, G, Schrappe, M, Schrauder, A

“…Minimal residual disease (MRD) quantified after induction treatment of childhood acute lymphoblastic leukemia (ALL) predicts risk of relapse. It has been…”
Get full text

Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials by Schrauder, A, von Stackelberg, A, Schrappe, M, Cornish, J, Peters, Christina

“…The definition of indications for allogeneic SCT in children with high-risk (HR) ALL in the first remission or after the first or subsequent relapse depends on…”
Get full text

Capture–recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003 by SCHRAUDER, A., CLAUS, H., ELIAS, J., VOGEL, U., HAAS, W., HELLENBRAND, W.

“…The incidence of invasive meningococcal disease (IMD) in Germany in 2003 was estimated by the two-source capture–recapture method. As a unique personal…”
Get full text

Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000 by Schrappe, M, Möricke, A, Reiter, A, Henze, G, Welte, K, Gadner, H, Ludwig, W-D, Ritter, J, Harbott, J, Mann, G, Klingebiel, T, Gruhn, B, Niemeyer, C, Kremens, B, Niggli, F, Debatin, K-M, Ratei, R, Stanulla, M, Beier, R, Cario, G, Schrauder, A, Zimmermann, M

“…Between 1981 and 2000, 6 609 children (<18 years of age) were treated in 5 consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood…”
Get more information

Allo-SCT using BU, CY and melphalan for children with AML in second CR by Beier, R, Albert, M H, Bader, P, Borkhardt, A, Creutzig, U, Eyrich, M, Ehlert, K, Gruhn, B, Greil, J, Handgretinger, R, Holter, W, Klingebiel, T, Kremens, B, Lang, P, Mauz-Körholz, C, Meisel, R, Müller, I, Peters, C, Reinhardt, D, Sedlacek, P, Schulz, A, Schuster, F R, Schrauder, A, Strahm, B, Sykora, K W, Wössmann, W, Zimmermann, M, Sauer, M G

“…Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively…”
Get full text

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients by MAECKER, B, MOUGIAKAKOS, D, ZIMMERMANN, M, BEHRENS, M, HOLLANDER, S, SCHRAUDER, A, SCHRAPPE, M, WELTE, K, KLEIN, C

“…Acute lymphoblastic leukemia (ALL) cells are particularly poor at generating anti-leukemia immunity, despite residing in lymphoid organs. To assess a potential…”
Get full text